Market News AIOpen the app

AKBA stock news · Akebia Therapeutics, Inc.

Stories about Akebia Therapeutics, Inc. (AKBA) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for AKBA

Follow Akebia Therapeutics, Inc. (AKBA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AKBA
Free on the App Store and Google Play, or on the web.
  1. Nov 16, 2026, 8:14 AM ET · Market

    Akebia Therapeutics has taken out a $140 million loan, starting with $60 million now.

    Bad for AKBA

    Akebia borrowed $60 million, received $58.6 million after fees, and repaid its old $55 million loan. The costly secured debt and warrants make this unfavorable for the company.

  2. Oct 14, 2026, 8:00 AM ET · Market

    Akebia Therapeutics says some directors and officers are leaving, and new ones are being chosen.

    Neutral

    Akebia’s commercial chief plans to leave in November for personal reasons, then advise through April 2027. The filing reports no wider business change, so it does not shift the company’s outlook.